miércoles, 2 de mayo de 2012

A Transfer of Power: Harnessing Patients' Immune Cells to Treat Their Cancer ▲ NCI Cancer Bulletin for May 1, 2012 - National Cancer Institute

NCI Cancer Bulletin for May 1, 2012 - National Cancer Institute

This is the first article in a two-part series on an immune-boosting therapy for cancer called adoptive cell transfer (ACT). Part one focuses on a form of ACT that uses tumor-infiltrating lymphocytes to treat advanced melanoma.
In the May 15 NCI Cancer Bulletin, part two will describe a form of ACT that uses genetically engineered T cells and is being investigated for the treatment of a variety of cancers. Part two will also explore the challenges of moving ACT from small clinical trials to everyday use in the clinic.

A Transfer of Power: Harnessing Patients' Immune Cells to Treat Their Cancer

Before and after pictures of a patient with advanced melanoma who underwent treatment with tumor-infiltrating lymphocytes.Before and after pictures of a patient with advanced melanoma who underwent treatment with tumor-infiltrating lymphocytes. Within 2 weeks of treatment, the large tumor had disappeared.
"These patients are probably cured" is not something most oncologists get to say about their patients with advanced cancer. Yet that's exactly how NCI's Dr. Steven Rosenberg describes a number of patients with advanced melanoma treated in three small clinical trials he has led at the NIH Clinical Center.
The patients in these trials—most of whom had tumors throughout their body (metastatic disease) and had nearly exhausted other treatment options—underwent a procedure known as adoptive cell transfer (ACT).
ACT involves removing some of a patient's own immune-system cells, growing billions of them in the laboratory, and returning them to the patient. The idea is to provide an invading force of immune cells that can attack tumors in a way that the immune system was incapable of doing on its own.
"The results in melanoma have been impressive," said Dr. Rosenberg, who, along with his colleagues in the Surgery Branch of NCI's Center for Cancer Research, has done pioneering work on ACT for more than a decade.
Based in large part on the Surgery Branch's success, a small but growing group of researchers at medical centers in the United States and abroad have launched their own programs to study ACT for melanoma and, increasingly, other cancers.
To date, only a few hundred patients have been treated with some form of ACT, but with the promising results reported thus far the treatment is gaining more attention and raising hopes among researchers in the field that it can one day be available to many more patients.
When TILs Attack
The ACT approach used in the three NCI trials entails collecting lymphocytes from patients' tumor samples, known as tumor-infiltrating lymphocytes (TILs), performing tests to identify the cells with the greatest antitumor activity, and then growing those particular cells in the laboratory over a period of weeks.
In this one-time-only treatment, the newly grown lymphocytes, composed primarily of T cells, are returned to the patient along with a cytokine (an immune-stimulating agent) called interleukin-2 (IL-2).
At high enough doses, IL-2 on its own can be a highly effective, even curative, treatment for a small proportion of patients with melanoma and advanced kidney cancer, explained Surgery Branch senior investigator Dr. James Yang. (IL-2 is approved by the Food and Drug Administration for both indications.) But it is difficult to administer and can have significant side effects, which have severely limited its use in clinical practice.
Before receiving the expanded TIL cells, patients also undergo lymphodepletion that consists of a round of chemotherapy and, in one of the treatment's current forms, whole-body radiation. The lymphodepletion "prepares patients to receive the infused lymphocytes without impediments," such as other immune cells that can thwart the incoming T-cell flood, Dr. Yang said.
The results to date are impressive. Of the 93 patients treated in the three trials, 20 have seen their tumors disappear completely (complete response); 19 of those 20 have remained tumor-free for longer than 5 years. (Most of these patients' tumors had not responded to other immunotherapy treatments.) Overall, tumors shrank substantially in 52 patients.
The idea [behind adoptive cell transfer] is to provide an invading force of immune cells that can attack tumors in a way that the immune system was incapable of doing on its own.
Several of the complete responses have extended beyond 8 years. "In my view, that's good evidence that we can probably cure some patients with metastatic melanoma," Dr. Rosenberg said. "And I don't use the term 'cure' lightly."
At the University of Texas MD Anderson Cancer Center, Dr. Patrick Hwu, who trained in NCI's Surgery Branch, has seen similar results in a small clinical trial of patients with metastatic melanoma. Half of the 50 patients treated at MD Anderson have had partial or complete tumor responses, he reported.
TIL therapy "is clearly one of the best treatments for metastatic melanoma," said Dr. Hwu. The use of TIL and other forms of ACT beyond NCI was an important step for the field, he stressed. "We had to prove it could be done at other centers."
As part of that process, researchers at established immunotherapy programs such as those at NCI and MD Anderson consult with their colleagues at other centers that are in the process of or hoping to set up their own programs. Dr. Hwu and his colleagues, for example, worked with researchers at the Moffitt Cancer Center in Florida to establish its immunotherapy program.
TIL therapy has moved overseas as well. Dr. Jacob Schachter leads a TIL therapy program at the Sheba Medical Center in Israel that is seeing similar results in patients with metastatic melanoma. Of the 51 patients treated to date, 6 have had complete responses, 15 have had partial responses, and a number of others have stable disease.
"Seventy percent of the clinical responders are still alive 2 years after treatment," he said.
Making Improvements
As promising as this treatment approach is, there are hurdles to overcome. Like other cancer therapies, TIL therapy has side effects. In addition to toxicities associated with IL-2 and the lymphodepletion regimen, the infusion of billions of T cells can trigger massive immune responses that can cause serious, potentially fatal, problems for patients. And for some patients, an army of T cells can't be grown.
Dr. Schachter's group is attempting to address the latter problem by focusing their efforts on "young" TILs, meaning that the lymphocytes removed from patients' tumors are grown for a shorter period in the laboratory and are not selected for expansion based on whether they exhibit antitumor activity in lab tests.
These "young" TILs, which Surgery Branch researchers are also investigating, "are relatively easy to grow compared to the 'selected TILs,'" Dr. Schachter explained, which has allowed the researchers to successfully formulate treatments for more patients.
Surgery Branch researchers have launched a trial of TILs that are genetically engineered to secrete the cytokine interleukin-12 when the TILs lock onto their molecular target on cancer cells. Some promising results have been seen in the first few patients to receive the treatment.
Dr. Hwu and his colleagues at MD Anderson are combining TIL therapy with other immunotherapies, such as dendritic cell vaccines and ipilimumab (Yervoy). They are also engineering TILs to express receptors to molecules known as chemokines that help guide them to cancer cells.
A major focus of his program's work, Dr. Hwu said, is to standardize the entire process. "We still can't grow TIL cells successfully for every patient," he said. "So we're constantly looking for ways to make the end product better and to grow cells for a higher percentage of patients."
There are clearly challenges to making TIL therapy more broadly available, Dr. Rosenberg acknowledged. But with further research, support, and experience, they can be overcome, he believes.
"If you have a deadly disease like melanoma and a treatment that can induce durable complete regressions of disease," he said, "people are going to want the treatment."
Carmen Phillips
From the Lab to the Clinic and Back
The TIL therapy regimen used by NCI's Surgery Branch serves as the foundation for the ACT treatments being studied at other centers around the world and has been refined based on laboratory and mouse model studies led by Surgery Branch researchers.
For example, mouse model studies led by Dr. Nicholas Restifo showed that more intense lymphodepletion with a radiation regimen made the treatment more effective, a finding that led to similar changes in the TIL regimen used in the NCI-led human trials. Of the three trials, the one that used the highest dose of radiation had the highest complete response rate: 10 of 25 patients, 9 of whose responses have persisted for at least 5 years.
Dr. Rick Morgan led the laboratory and mouse model studies of TILs engineered to express IL-12—an important advance because, although IL-12 can potently kill tumors in mice, it is highly toxic and potentially fatal when administered systemically in humans.
The iterative nature of the process is a cornerstone of the Surgery Branch's work. "I think that's the really unique feature of the NIH Clinical Center and the NIH intramural program," said Dr. Yang. "We can sit together at lunch, talk about results we're seeing in the clinic and how they apply to our lab studies. [We talk about] what's happening with our lab studies and how they should influence our approach in the clinic. It's as quick and productive as anything I've ever been involved in."

No hay comentarios:

Publicar un comentario